CABA logo

CABA
Cabaletta Bio Inc

3,650
Mkt Cap
$327.29M
Volume
915,849.00
52W High
$3.78
52W Low
$1.11
PE Ratio
-1.28
CABA Fundamentals
Price
$2.94
Prev Close
$2.99
Open
$2.99
50D MA
$3.08
Beta
1.69
Avg. Volume
1.96M
EPS (Annual)
-$2.10
P/B
2.64
Rev/Employee
$0.00
$68.49
Loading...
Loading...
News
all
press releases
Stock Traders Buy High Volume of Call Options on Cabaletta Bio (NASDAQ:CABA)
Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) saw unusually large options trading on Wednesday. Stock investors acquired 11,001 call options on the stock. This is an increase of 756% compared...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Wall Street Zen Downgrades Cabaletta Bio (NASDAQ:CABA) to Sell
Wall Street Zen downgraded shares of Cabaletta Bio from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·15d ago
News Placeholder
First Patients Dosed with Cabaletta Bios Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.s (Cabaletta Bio or Cabaletta) (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has been infused into the first two patients using drug...
Business Wire·18d ago
News Placeholder
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Moderate Buy" by Analysts
Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One...
MarketBeat·20d ago
News Placeholder
Cabaletta Bio, Inc. $CABA Position Raised by JPMorgan Chase & Co.
JPMorgan Chase & Co. raised its stake in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 565.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional...
MarketBeat·23d ago
News Placeholder
Q1 EPS Estimates for Cabaletta Bio Raised by HC Wainwright
Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Research analysts at HC Wainwright boosted their Q1 2026 EPS estimates for shares of Cabaletta Bio in a research note issued on Wednesday, April 1st. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.3...
MarketBeat·30d ago
News Placeholder
Cabaletta Bio (NASDAQ:CABA) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen upgraded Cabaletta Bio from a "strong sell" rating to a "hold" rating in a report on Sunday...
MarketBeat·1mo ago
News Placeholder
Morgan Stanley Cuts Cabaletta Bio (NASDAQ:CABA) Price Target to $13.00
Morgan Stanley reduced their target price on shares of Cabaletta Bio from $14.00 to $13.00 and set an "overweight" rating on the stock in a research report on Tuesday...
MarketBeat·1mo ago
News Placeholder
Guggenheim Forecasts Strong Price Appreciation for Cabaletta Bio (NASDAQ:CABA) Stock
Guggenheim boosted their target price on shares of Cabaletta Bio from $15.00 to $16.00 and gave the company a "buy" rating in a report on Tuesday...
MarketBeat·1mo ago
News Placeholder
Cabaletta Bio (NASDAQ:CABA) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
Cabaletta Bio (NASDAQ:CABA - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.05...
MarketBeat·1mo ago
<
1
2
...
>

Latest CABA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.